7 results about "Basilar membrane" patented technology

Presented herein are systems and methods of providing acoustic stimulation to a human subject in order to evoke an auditory response. The method includes generating a chirp signal, where generating the chirp signal includes adding a plurality of frequency signals, each frequency signal being delayed in the chirp signal based on its associated frequency-specific basilar membrane delay, the frequency-specific basilar delay being determined as a function of an in-vivo frequency-specific basilar membrane delay.

This invention relates to the field of cochlear basilar membrane anatomy technology with integrated microscopic vision, and discloses an integrated microscopic cochlear basilar membrane anatomy instrument platform, including a fixing mechanism fixedly connected to the inner wall of the groove to reduce the height difference between the liquid and the outlet during liquid extraction. A storage mechanism rotatably connected to the inner wall of the fixing mechanism stores the liquid. A deceleration mechanism fixedly connected to the outer wall of the fixing mechanism slows down the movement speed of the device. This prevents hydrostatic pressure loss as the liquid level drops, which would result in insufficient initial force for the liquid to enter the outlet tube, slowing down the liquid delivery efficiency, preventing timely replenishment of the physiological solution, causing osmotic pressure imbalance in the sample, and ultimately deforming the sample, rendering it unusable.

The invention provides an automatic analysis method for severity of cochlea lost hydrops. The method comprises the following steps: acquiring a microscopic image of a certain animal cochlea pathology; preprocessing the microscopic image; automatically segmenting the cochlea structure of the preprocessed microscopic image; automatically extracting a cochlear tube contour surrounded by a vestibular membrane and a basilar membrane in a cochlea structure of the microscopic image and a structure contour on the cochlea basilar membrane, and manually correcting the extracted contours; and automatically calculating the ratio of S1 to S and obtaining the analysis result of the severity degree of cochlea lost hydrops based on the artificially corrected area S1 corresponding to the contour of the cochlea tube surrounded by the vestibular membrane and the basilar membrane and the area S corresponding to the contour of the structure on the cochlea basilar membrane. According to the method, the vacancy of quantitative analysis tools for cochlear hydrops is filled, the method serves for otology basic research and vestibular disease research, and more efficient and objective technical support is provided for mechanism research and treatment evaluation of inner ear diseases such as Meniere disease and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to application of neratinib in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the neratinib in preparation of the medicine for preventing and treating hearing impairment / deafness is provided. According to the invention, the fact that neratinib can play a hearing protection role by specifically regulating and controlling cochlea immune microenvironment is found for the first time, and the hearing protection role is specifically realized by the following mechanisms: regulating and controlling biological effects such as cell signal channels, inflammatory response and cell stress response, protecting hair cell structures, and reducing cochlea basilar membrane outer hair cell loss caused by noise exposure. Based on the new discovery of the invention, the neratinib can be used for preparing medicines for preventing and treating hearing impairment and deafness caused by noise.

Diagnosing and treating presbycusis (age related hearing loss) includes measuring basilar membrane stiffness. In an example, a low frequency component of an electrocochleogram stimulation signal is used to bias a region of the basilar membrane, the results of which are used basilar membrane stiffness. The resulting measurement is used to measure a subcomponent of presbycusis. Further, the measurement can be combined with known diagnostic methods to reveal or distinguish other origins of hearing loss such as strial presbycusis, sensory presbycusis, neural presbycusis, and cochlea conductive presbycusis. The relative contributions for each of the diagnosed origins of hearing loss can be determined.

The invention belongs to the field of biological medicines, and particularly relates to application of penicillamine in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the penicillamine in preparing the medicine for preventing and treating hearing impairment / deafness is provided. The hearing disorder and / or deafness is caused by noise. It is found for the first time that penicillamine can play a hearing protection role by specifically regulating a cochlea immune microenvironment, and the hearing protection role is specifically achieved through the following mechanisms: inhibition of T cell activation: interference of a TCR signal channel; the hair cell structure is protected; the cochlea basilar membrane outer hair cell loss caused by noise exposure is reduced. Based on the new discovery of the invention, the penicillamine can be used for preventing and treating hearing impairment and deafness caused by noise.

The application belongs to the technical field of gene therapy, and particularly relates to an AAV capsid protein mutant targeting glial cells and application thereof. The AAV capsid protein mutant is constructed by inserting a polypeptide with glial cell infection characteristics between N589 and R590 of an AAV-DJ capsid protein amino acid sequence, and exhibits enhanced transduction and targeting in inner ear basal membrane supporting cells, and has the function of enhancing supporting cell transduction in the cochlear basal membrane of newborn and adult mice, thereby being capable of solving the problem of low transduction efficiency of AAV in the cochlear basal membrane supporting cells of adult mice, and providing a potentially available tool for gene therapy of deafness genes positioned in supporting cells by Chen et al. GJB2 and the like.